Vectura Group

EQS-News: Atriva Therapeutics appoints Christian Pangratz as CEO, implementing planned management change

Retrieved on: 
Friday, November 11, 2022
Marketing, IZB, Business development, Degenerative disease, Research, Advisory board, Sale, Board, Doctor of Philosophy, Therapy, RNA, Coronavirus, Virus, Webster University, Orthornavirae, Nektar Therapeutics, Patient, Bayer, CEO, Business, COVID-19, POC, Management, Vaccine, Pharmaceutical industry, Pfizer, Vectura Group, EU

Atriva Therapeutics appoints Christian Pangratz as CEO, implementing planned management change

Key Points: 
  • Atriva Therapeutics appoints Christian Pangratz as CEO, implementing planned management change
    The issuer is solely responsible for the content of this announcement.
  • Atriva Therapeutics appoints Christian Pangratz as Chief Executive Officer,
    Christian Pangratz to become Chief Executive Officer of Atriva Therapeutics GmbH effective January 15, 2023
    With positive POC data from RESPIRE study and strengthened management team, Atriva ready for next phase of growth
    Tbingen, Frankfurt am Main, Martinsried, Germany, November 9, 2022 Today, Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced the appointment of Christian Pangratz as Chief Executive Officer (CEO), effective January 15, 2023.
  • It is a great pleasure to welcome Christian Pangratz as the new CEO of Atriva.
  • Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, commented: I am honored to have Christian Pangratz succeed me at CEO.

Theolytics presents CAF-targeting therapy for stromal rich tumours, and strengthens leadership team as pipeline accelerates into the clinic

Retrieved on: 
Thursday, October 6, 2022
Potyvirus, CFO, Time, Conference, Virus, IPO, Biotechnology, Patient, CAFS, Entrepreneurship, Cancer, Actelion, Fibroblast, Foundation, Vectura Group, Pharmaceutical industry

Stromal rich cancers pose a challenge to many cancer therapies due to the abundance of cancer associated fibroblasts (CAFs).

Key Points: 
  • Stromal rich cancers pose a challenge to many cancer therapies due to the abundance of cancer associated fibroblasts (CAFs).
  • THEO-260 is a new oncolytic virus in development that is intrinsically capable of targeted killing of both cancer cells and CAFs.
  • Theolytics' Chief Scientific Officer and Co-Founder, Margaret Duffy shared "up to 60% of the tumour volume of many solid cancers is CAF-rich stroma.
  • "I warmly welcome Andrew and Miriam to our leadership team" comments Charlotte Casebourne, Chief Executive Officer and Co-Founder of Theolytics.

Theolytics presents CAF-targeting therapy for stromal rich tumours, and strengthens leadership team as pipeline accelerates into the clinic

Retrieved on: 
Thursday, October 6, 2022
Potyvirus, CFO, Time, Conference, Virus, IPO, Biotechnology, Patient, CAFS, Entrepreneurship, Cancer, Actelion, Fibroblast, Foundation, Vectura Group, Pharmaceutical industry

Stromal rich cancers pose a challenge to many cancer therapies due to the abundance of cancer associated fibroblasts (CAFs).

Key Points: 
  • Stromal rich cancers pose a challenge to many cancer therapies due to the abundance of cancer associated fibroblasts (CAFs).
  • THEO-260 is a new oncolytic virus in development that is intrinsically capable of targeted killing of both cancer cells and CAFs.
  • Theolytics' Chief Scientific Officer and Co-Founder, Margaret Duffy shared "up to 60% of the tumour volume of many solid cancers is CAF-rich stroma.
  • "I warmly welcome Andrew and Miriam to our leadership team" comments Charlotte Casebourne, Chief Executive Officer and Co-Founder of Theolytics.

Seventy Percent (70%) of Patients Surveyed Voice Concern About Tobacco Corporations’ Ownership of Lung Disease Treatments

Retrieved on: 
Monday, August 15, 2022
Tobacco, Health, General Health, Healthcare Reform, Public Policy, Seniors, Research, Retail, Public Policy, Government, Consumer, Science, Linda, Health insurance coverage in the United States, Smoker, PMI, Chronic lung disease, CEO, Asthma, Philip Morris International, Winders, Sale, Smoking, British Thoracic Society, Chronic obstructive pulmonary disease, Caregiver, Research, Human, Foundation, Patient, Twitter, Education, Degenerative disease, NTM, Awareness, COPD, Doctor of Philosophy, Bronchiectasis, Respiratory disease, Ownership, Journal, MD, LinkedIn, Disease, Pharmaceutical industry, Health insurance, Medicine, Thorax, Vectura Group

The survey gave people with chronic lung disease a voice in the conversation about tobacco corporations owning companies that develop tools and medications to treat lung conditions.

Key Points: 
  • The survey gave people with chronic lung disease a voice in the conversation about tobacco corporations owning companies that develop tools and medications to treat lung conditions.
  • Based on the surveys findings, as reported in Thorax, most patients care deeply that tobacco companies have a financial stake in drug or device companies and profit from life-saving treatment.
  • Vectura develops several widely used medical delivery devices and/or formulations for inhaled therapies used in people with chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma.
  • It is morally wrong,
    They made lots of money; they should research and develop treatments for those that used their products.

Paul Fry appointed as Argenta’s new Chief Financial Officer

Retrieved on: 
Monday, June 27, 2022
Health, Research, Pharmaceutical, Science, Biotechnology, Veterinary, Gavin Downie, Acquisition, Vodafone, CEO, GSK, Research, KKR, Contract research organization, Telecommunication, Growth, Ownership, TCR, GMP, CDMO, CRO, CFO, Contract, London Stock Exchange, United Kingdom, Partnership, Asota avacta, Chartered Institute of Management Accountants, Technology, Management accounting, Vectura Group, University of Oxford, Health, Audit committee, Time, List of professional associations in the United Kingdom, Management, Renewable energy

Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately.

Key Points: 
  • Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately.
  • Paul Fry has extensive financial experience across several industries including biotech, pharmaceuticals, and telecommunications.
  • Before Vectura, Paul was Chief Financial Officer of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor (TCR) technology.
  • Paul Fry said: It is an exciting time to enter the animal health industry and I am delighted to be joining Argenta.

Philip Morris International Releases 2021 Integrated Report, Introducing New Sustainability Strategy and Sustainability Index

Retrieved on: 
Tuesday, May 17, 2022
Other Consumer, Consumer, Environment, Retail, Tobacco, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., Form, Public health, Food, Smoke, USD, Farmer, Smoking, Lists of disasters, PMI, Private Securities Litigation Reform Act, GRI, Annual report, Tobacco, IQOS, Income, Regulation of tobacco by the U.S. Food and Drug Administration, Toxicology, Integrated reporting, Woman, Marketing, Research, Information, NYSE, Value, United Nations Global Compact, Health, Achievement, Materiality, Vectura Group, Goal, Science, Uncertainty, Smoker, Solution, Eye, Adult, FDA, Integration, Recycling, VRF, Global warming potential, Philip Morris International, Privacy, Task force, Global, Intellectual property, Nicotine, Technology, Safety, Sale, KPI-driven code analysis, Forest, ESG, Management, Risk management, Animal, Renewable energy, Agriculture, Fertin Pharma

The content was informed by a formal sustainability materiality assessment conducted in 2021.

Key Points: 
  • The content was informed by a formal sustainability materiality assessment conducted in 2021.
  • The companys 2021 sustainability materiality assessment helped identify the ESG issues on which PMI should prioritize and focus its resources.
  • Altogether, these KPIs make up the companys new Sustainability Index, which explicitly links 30% of the companys long-term compensation program to ESG performance.
  • To read the report, visit PMI Integrated Report 2021 ; to find out more about sustainability at PMI, please click here to visit the website .

Argenta Appoints Will Downie as Chief Executive Officer

Retrieved on: 
Tuesday, April 19, 2022
Science, Veterinary, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Board, CEO, CDMO, R, Leadership, Vectura Group, GMP, Growth, Gavin Downie, Catalent, CRO, The Conference Board, Contract research organization, Health, Contract, Time, Management, Fine chemical

Argenta today announced that the companys Board of Directors has appointed Will Downie as Chief Executive Officer, effective immediately.

Key Points: 
  • Argenta today announced that the companys Board of Directors has appointed Will Downie as Chief Executive Officer, effective immediately.
  • Will Downie succeeds interim CEO Stephen Sibson, who will resume his role as Argentas Global Head of Manufacturing.
  • I am delighted to have accepted the role of CEO of Argenta and to have the opportunity to be part of the worlds only integrated CRO/CDMO animal health company.
  • Argenta is the only combined global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) dedicated to animal health.

Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Therapy, FTSE, Board, Monaco Age Oncologie, Degenerative disease, NASDAQ, Security (finance), Annual report, CFO, Form 6-K, Neoplasm, Sanofi, Industry, Company, OI, Audit, U.S. Securities and Exchange Commission, FCA, AATD, KPMG, Vulnerability and Risk Committee, Trinity College, Cancer, Audit committee, Patient, CTA, Forward-looking statement, Osteogenesis imperfecta, Ovarian cancer, Pharmaceutical industry, Management, Vectura Group

LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), Mereo or the Company, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Companys Board of Directors, effective immediately.

Key Points: 
  • LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), Mereo or the Company, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Companys Board of Directors, effective immediately.
  • Ms. Hyland joins Mereos Board with over 30 years of financial experience in both private and public companies in the biopharmaceutical space.
  • We are very excited to welcome someone with Annes level of operational and board experience to our Board, said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo.
  • I am honored to be joining the Mereo Board at such a pivotal time for the Company, said Ms. Hyland.

Philip Morris International Inc. (PMI) Presents at the 2022 Consumer Analyst Group of New York (CAGNY) Virtual Conference

Retrieved on: 
Wednesday, February 23, 2022
Tobacco, Retail, Smoke, Information, Intellectual property, Growth, IQOS, Regulation of tobacco by the U.S. Food and Drug Administration, Public health, Tobacco, Privacy, Annual report, COVID-19, PMI, Sale, Smoking, Private Securities Litigation Reform Act, NYSE, Safety, EPS, Achievement, Travel, Woman, Adult, Food, Philip Morris International, Recurrence, MRTP, Vectura Group, Toxicology, Leadership, FDA, Conference, Marketing, Technology, Knowledge, Lists of disasters, Solution, Research, Smoker, Event-driven architecture, IOS, Healthcare, Risk management, Android, Fertin Pharma

Philip Morris International Inc.s (NYSE: PM) Chief Executive Officer, Jacek Olczak, and Chief Financial Officer, Emmanuel Babeau, address investors today at the 2022 Consumer Analyst Group of New York (CAGNY) Virtual Conference.

Key Points: 
  • Philip Morris International Inc.s (NYSE: PM) Chief Executive Officer, Jacek Olczak, and Chief Financial Officer, Emmanuel Babeau, address investors today at the 2022 Consumer Analyst Group of New York (CAGNY) Virtual Conference.
  • The video can also be accessed on iOS or Android devices by downloading PMIs free Investor Relations Mobile Application at www.pmi.com/irapp .
  • At this time, we do not anticipate any material impact on our business related to the announced sanctions.
  • The presentation, related discussion and this press release contain projections of future results and other forward-looking statements.

EnBiotix, Inc. Closes $11M Pre-Merger Financing

Retrieved on: 
Wednesday, December 29, 2021
Safety, SIX Swiss Exchange, Disease, Technology, NTM, SBL, Trial of the century, Mortality, Sanford Burnham Prebys Medical Discovery Institute, Funding, CA, Degenerative disease, GLOBE, Hospital, Foundation, CEO, Therapy, Philip Morris International, Patient, Program, Â, Cystic Fibrosis Foundation, EFlow, Conditional sentence, Cystic fibrosis, Pharmaceutical industry, Fine chemical, Allschwil, Vectura Group

The Financing was led by Vectura Group plc (Vectura), a leader in inhaled therapeutics and drug-device combination development.

Key Points: 
  • The Financing was led by Vectura Group plc (Vectura), a leader in inhaled therapeutics and drug-device combination development.
  • Sanford Biosciences LLC (SBL), a past investor in EnBiotix, also joined the Financing.
  • The Financing is designed to enable initiation of a number of EnBiotix activities related to the planned global Phase 3 clinical study of ColiFin in cystic fibrosis patients.
  • The proceeds from the financing will significantly accelerate our plans to deliver innovative products to cystic fibrosis and other rare disease patients with significant unmet needs.